| A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants with Type 2 Diabetes during Ramadan (T-RAM) |
Ongoing |
Tirzepatide |
4 |
I8F-MC-GPIY |
Al Moosa Specialized Hospital (al ahsa), King Faisal Specialist Hospital and Research Center (Riyadh), Saudi Airlines Medical Service Center (Jeddah), King Fahad Medical City (Riyadh), Dallah Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Faisal Specialist Hospital and Research Center (Madinah) |
| CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease |
Ongoing |
Camizestrant (AZD9833) |
3 |
8535C00001 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 18 years and older with moderate-to-severe atopic dermatitis (AD) who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase (JAK) inhibitor treatment |
Ongoing |
amlitelimab |
3 |
EFC17599 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi-Center, Open Label, Single Arm, Phase II, PET-Adaptive Study |
Ongoing |
Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine |
2 |
RJ19/119/J |
King Abdullah Medical Complex (Jeddah) |
| A Randomized Controlled Trial Comparing Blood Glucose Control Intraoperative Between Insulin Drip vs. Insulin Boluses |
Ongoing |
Insulin |
3 |
2023-45 |
King Faisal Specialist Hospital and Research Center (Jeddah) |
| The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency |
Ongoing |
INZ701 |
3 |
INZ701-106 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Long-term pain and adherence observational study for Endometriosis treatment |
Ongoing |
Duphaston |
4 |
DYDR-522-0318 |
Dr.Arab Clinic |
| Real world Assessment of Dyslipidemia patients on Inclisiran effiCacy And toLerability: The RADICAL Study |
Ongoing |
LEQVIO |
4 |
CKJX839A1S |
Dallah Hospital (Riyadh),International Medical Center (Jeddah), Armed Force Hospital (Tabuk) , My Clinic (Jeddah) Mouwasat Hospital (Dammam) |
| Effect of celecoxib on postoperative narcotic use and disease severity in patients with aspirin-exacerbated respiratory disease and chronic rhinosinusitis: a randomized controlled trial |
Ongoing |
Celecoxib |
4 |
114809 |
King Khalid University Hospital (Riyadh) King Abdulaziz University Hospital (Riyadh) |
| EASi-HF - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) >40% |
Ongoing |
BI 690517 , empagliflozin |
3 |
1378-0020 |
1-King Fahad Medical City (Riyadh) 2-King Khalid University Hospital (Riyadh) 3-King Faisal Specialist Hospital and Research Center (Riyadh) 4-King Abdulaziz Medical City NG (Riyadh) 5-King Abdulaziz University Hospital (Jeddah) |
